Key facts
- It has raised $273.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($165.0M) in Dec 2023.
- 3 institutional filers report fund marks on Bicara Therapeutics across 13 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Bicara Therapeutics
Create free account
No card required
Funding rounds
2 roundsDec 2023Later Stage VC (Series C)$165.0M▮
Sep 2023Later Stage VC (Series B)$108.0M▮
About Bicara Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Bicara Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Bicara Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
3 filers · latest May 20263 SEC-registered funds reported 13 fair-value marks on Bicara Therapeutics between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.